National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Bempedoic acid (Nilemdo®) HTA ID: 20026a

Nilemdo® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet:

▪ In combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or

▪ Alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated


NCPE Assessment Process Complete
Rapid review commissioned 15/06/2020
Rapid review completed 03/07/2020
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of bempedoic acid compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 06/07/2020
Pre submission consultation with Applicant 22/09/2020
Current Status Awaiting HTA submission from Applicant